Navigation Links
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
Date:10/29/2013

PITTSBURGH, Oct. 29, 2013 /PRNewswire-iReach/ -- Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs.  GPCRs are the most common target of today's blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer.  "While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work.  These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets" said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.  

(Photo: http://photos.prnewswire.com/prnh/20131029/MN04907)

"Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds" added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics.  "Several large-pharma customers are already using the technology to study so-called 'ligand bias' or 'functional selectivity' of GPCRs.  By combining SpectraGenetics' catalog of over 150 GPCRs with Sharp Edge Labs' assay development expertise, we believe we can help researchers address any question in this important new field of drug research" he added.

SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs.  SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs.   Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters.  The company's web-sites are www.spectragenetics.com and www.sharpedgelabs.com.  Detailed images of the technology in use  suitable for print or web publication can be found at www.sharpedgelabs.com/media-images

Media Contact: Scott Sneddon, PhD, JD, Sharp Edge Labs, Inc., 412-475-9733, scott@sharpedgelabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Sharp Edge Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rehrig Pacific Company Receives FDA Approval for New Reusable Sharps Container
2. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
3. Safe in Commons "The Unfinished Agenda: Addressing the Challenges" Crystalizes Call for Unified Protection Against Needlestick and Sharps Injuries
4. Brain Resource Featured as Market Leader in SharpBrains New Report on The State of the Digital Brain Health Market 2012-2020
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
7. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
8. Philips and Infraredx sign agreement for the resale of Infraredxs TVC Imaging System integrated with Philips interventional X-ray systems
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
11. Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017 Caris Life Sciences, a leading ... promise of precision medicine, today announced results from ... its molecular profiling approach in guiding therapeutic strategies ... plus (CGP+) with Caris Molecular Intelligence ® ... molecular level, leading to more therapeutic options and ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017   PDI , a leader in infection ... an educational session focused on the role of chlorhexidine ... at the 2017 Annual Scientific Meeting of the Association ... at the Phoenix Convention Center ... 16-19, will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... “Fruit of ... their imaginations while exploring nature that God has created. “Fruit of the Spirit: “Love”” ... Muslim, is now a devoted wife and mother of five. Halimah is an avid ...
(Date:9/22/2017)... Greenwich, Connecticut (PRWEB) , ... September 22, 2017 ... ... to conquering Lyme and other tick-borne diseases through research, education and awareness, today ... , A noted immunologist and microbiologist, Dr. Sellati has more than 20 ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness ... September 11 to the end of November. , The Chicago, Illinois, based self-defense brand ... and teach them about the ease of taking their personal safety into their own ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and continued ... have been awarded five-year accreditation status through the Public Health Accreditation Board ... by a PHAB-accredited health department now extend to more than 203 million ...
(Date:9/21/2017)... , ... September 21, 2017 , ... The New England ... autism, announced today the election of Yie-Hsin Hung to the Board of Directors. ... our Board of Directors. Ms. Hung is an invaluable addition to our team,” said ...
Breaking Medicine News(10 mins):